Cure8 research brief
This study tests a common clinical question: whether increasing vedolizumab frequency helps patients who show no endoscopic response after 6 months. The results suggest intensification raised drug levels but did not improve remission rates, which may influence decisions about switching therapies versus dose escalation.
Adult patients with Crohn’s disease on vedolizumab, clinicians managing biologic therapy, researchers studying biologic dose optimization
The trial compared patients who remained on standard vedolizumab dosing with those who were switched to every‑4‑week dosing because they had <50% improvement in SES‑CD at Week 26. Intensified dosing raised vedolizumab serum concentrations significantly, yet did not increase rates of deep remission, endoscopic remission, or clinical remission by Week 52.
Severe adverse event rates were similar between groups.
The content is based on the article abstract (structured content depth: abstract). The study focused on endoscopic nonresponders after 26 weeks; results may not generalize to other patient subgroups or to strategies used for secondary loss of response.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Postoperative recurrence after ileocolonic resection is common in Crohn’s disease. This randomized trial suggests vedolizumab can reduce early endoscopic recurrence, offering an additional biologic option for preventing...
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
